Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression

Gang Zhou, Zhengbin Lu, John D. McCadden, Hyam I. Levitsky, Aimee L. Marson

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Two seemingly incompatible models exist to explain the progression of cancers in immunocompetent hosts. The cancer immunosurveillance hypothesis posits that recognition of transformed cells by the immune system results in the generation of an effector response that may impede tumor growth. Clinically detectable cancer results from the emergence of tumor variants that escape this selective pressure. Alternatively, induction of immune tolerance to tumor antigens may enable cancer progression. We established a model where changes in the function of tumor-specific T cells and in tumor antigen expression could be followed during cancer progression. Early recognition of antigen led to activation, expansion, and effector function in tumor-specific CD4+ T cells resulting in the outgrowth of tumors expressing substantially reduced levels of antigen. Antigen loss was not complete, however, and levels remained above the threshold required for tumor-specific T cell recognition in vivo. In the face of persisting antigen, T cell tolerance ensued, leading to an impaired ability to mediate further antigen loss. Together, these studies establish that the processes of immunosurveillance and tumor editing coexist with a process in which the functional tumor-specific T cell repertoire is also "edited," reconciling two hypotheses historically central to our attempts to understand host antitumor immunity.

Original languageEnglish (US)
Pages (from-to)1581-1592
Number of pages12
JournalJournal of Experimental Medicine
Volume200
Issue number12
DOIs
StatePublished - Dec 20 2004
Externally publishedYes

Fingerprint

Neoplasm Antigens
T-Lymphocytes
Neoplasms
Antigens
Immunologic Monitoring
Tumor Escape
Immune Tolerance
Immune System
Immunity

Keywords

  • Immune tolerance
  • Immunoediting
  • Immunosurveillance
  • T lymphocyte
  • Tumor escape

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. / Zhou, Gang; Lu, Zhengbin; McCadden, John D.; Levitsky, Hyam I.; Marson, Aimee L.

In: Journal of Experimental Medicine, Vol. 200, No. 12, 20.12.2004, p. 1581-1592.

Research output: Contribution to journalArticle

Zhou, Gang ; Lu, Zhengbin ; McCadden, John D. ; Levitsky, Hyam I. ; Marson, Aimee L. / Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. In: Journal of Experimental Medicine. 2004 ; Vol. 200, No. 12. pp. 1581-1592.
@article{a6a34294f0c44197b03718f73a29238c,
title = "Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression",
abstract = "Two seemingly incompatible models exist to explain the progression of cancers in immunocompetent hosts. The cancer immunosurveillance hypothesis posits that recognition of transformed cells by the immune system results in the generation of an effector response that may impede tumor growth. Clinically detectable cancer results from the emergence of tumor variants that escape this selective pressure. Alternatively, induction of immune tolerance to tumor antigens may enable cancer progression. We established a model where changes in the function of tumor-specific T cells and in tumor antigen expression could be followed during cancer progression. Early recognition of antigen led to activation, expansion, and effector function in tumor-specific CD4+ T cells resulting in the outgrowth of tumors expressing substantially reduced levels of antigen. Antigen loss was not complete, however, and levels remained above the threshold required for tumor-specific T cell recognition in vivo. In the face of persisting antigen, T cell tolerance ensued, leading to an impaired ability to mediate further antigen loss. Together, these studies establish that the processes of immunosurveillance and tumor editing coexist with a process in which the functional tumor-specific T cell repertoire is also {"}edited,{"} reconciling two hypotheses historically central to our attempts to understand host antitumor immunity.",
keywords = "Immune tolerance, Immunoediting, Immunosurveillance, T lymphocyte, Tumor escape",
author = "Gang Zhou and Zhengbin Lu and McCadden, {John D.} and Levitsky, {Hyam I.} and Marson, {Aimee L.}",
year = "2004",
month = "12",
day = "20",
doi = "10.1084/jem.20041240",
language = "English (US)",
volume = "200",
pages = "1581--1592",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "12",

}

TY - JOUR

T1 - Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression

AU - Zhou, Gang

AU - Lu, Zhengbin

AU - McCadden, John D.

AU - Levitsky, Hyam I.

AU - Marson, Aimee L.

PY - 2004/12/20

Y1 - 2004/12/20

N2 - Two seemingly incompatible models exist to explain the progression of cancers in immunocompetent hosts. The cancer immunosurveillance hypothesis posits that recognition of transformed cells by the immune system results in the generation of an effector response that may impede tumor growth. Clinically detectable cancer results from the emergence of tumor variants that escape this selective pressure. Alternatively, induction of immune tolerance to tumor antigens may enable cancer progression. We established a model where changes in the function of tumor-specific T cells and in tumor antigen expression could be followed during cancer progression. Early recognition of antigen led to activation, expansion, and effector function in tumor-specific CD4+ T cells resulting in the outgrowth of tumors expressing substantially reduced levels of antigen. Antigen loss was not complete, however, and levels remained above the threshold required for tumor-specific T cell recognition in vivo. In the face of persisting antigen, T cell tolerance ensued, leading to an impaired ability to mediate further antigen loss. Together, these studies establish that the processes of immunosurveillance and tumor editing coexist with a process in which the functional tumor-specific T cell repertoire is also "edited," reconciling two hypotheses historically central to our attempts to understand host antitumor immunity.

AB - Two seemingly incompatible models exist to explain the progression of cancers in immunocompetent hosts. The cancer immunosurveillance hypothesis posits that recognition of transformed cells by the immune system results in the generation of an effector response that may impede tumor growth. Clinically detectable cancer results from the emergence of tumor variants that escape this selective pressure. Alternatively, induction of immune tolerance to tumor antigens may enable cancer progression. We established a model where changes in the function of tumor-specific T cells and in tumor antigen expression could be followed during cancer progression. Early recognition of antigen led to activation, expansion, and effector function in tumor-specific CD4+ T cells resulting in the outgrowth of tumors expressing substantially reduced levels of antigen. Antigen loss was not complete, however, and levels remained above the threshold required for tumor-specific T cell recognition in vivo. In the face of persisting antigen, T cell tolerance ensued, leading to an impaired ability to mediate further antigen loss. Together, these studies establish that the processes of immunosurveillance and tumor editing coexist with a process in which the functional tumor-specific T cell repertoire is also "edited," reconciling two hypotheses historically central to our attempts to understand host antitumor immunity.

KW - Immune tolerance

KW - Immunoediting

KW - Immunosurveillance

KW - T lymphocyte

KW - Tumor escape

UR - http://www.scopus.com/inward/record.url?scp=11844302141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844302141&partnerID=8YFLogxK

U2 - 10.1084/jem.20041240

DO - 10.1084/jem.20041240

M3 - Article

C2 - 15596524

AN - SCOPUS:11844302141

VL - 200

SP - 1581

EP - 1592

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 12

ER -